Thomson Reuters to divest healthcare unit

Mary Stevens | | Health Exec | Economics
Thomson Reuters is divesting its healthcare business, which provides data, analytics and performance benchmarking technologies and services to companies, government agencies and healthcare professionals, by the end of the year.

Thomson Reuters Healthcare is a unit of the company’s Healthcare & Science segment. The unit—which had revenues of approximately $450 million in 2010—is expected “to attract substantial demand from buyers as we sell into a consolidating market,” the New York City-based company predicted.

The decision to sell the healthcare unit was due to its lack of integration with the global scale of other units, and “the expected proceeds from a sale into a consolidating market could be better applied elsewhere in our portfolio,” stated Thomas H. Glocer, CEO of Thomson Reuters.

Following adjustment for this divestiture by removing the healthcare unit’s results from ongoing businesses, no material impact is expected to the company’s previously announced 2011 outlook, according to the company.

Morgan Stanley and Allen are acting as financial advisors to Thomson Reuters for the proposed divestiture.

Mary Stevens

Related Content

Cardiologist demand is on the rise—can hospitals keep up?
Cardinal Health scoops up two companies for $3.9B
UnitedHealth defends $3.3B Amedisys acquisition
DOJ sues to block UnitedHealth’s $3.3B acquisition of home health giant
Private equity firm to buy Summa Health for $485M
Private equity transactions in healthcare down 15% since 2023, report finds

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup